Arteriosclerosis
Not recruitingStudy on Inclisiran for Preventing Heart Disease in High-Risk Patients
- Disease:Arteriosclerosis
- Substances:Inclisiran
Czechia- Participants:18–64 years · 65+ years
- Substances:Inclisiran
- Sponsor:Novartis Pharma AG
Rare diseases
Investigational molecules
Locations
Back to Czechia14 clinical trials in Chlumec Nad Cidlinou, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in CzechiaKlinickeTesty.cz(opens in a new tab)
Czechia
CzechiaThe busiest research cities in the country
What the registry says about research in the country
Research focusing on primary prevention of atherosclerotic cardiovascular disease and innovative approaches to prevent heart failure development in high-risk patients.
These trials aim to evaluate new therapeutic combinations for reducing cardiovascular events in at-risk populations.
Investigations into advanced treatments for hypercholesterolemia and innovative therapies targeting lipoprotein management in cardiovascular disease patients.
Studies focus on evaluating novel approaches to achieve optimal lipid levels and improve patient outcomes.
Clinical research examining treatments for acute decompensated heart failure and strategies to reduce cardiovascular mortality in patients with established heart conditions.
These investigations aim to enhance therapeutic options for patients with various forms of heart failure.
Tell us about your condition – we search every trial in Europe and connect you with the right site.